Theravance Pushes On With Gastroparesis Candidate Amid Mixed Data
Theravance is working out what to do next with its investigational drug for gastroparesis after it produced mixed data in a Phase IIb trial in this underserved indication.
You may also be interested in...
Theravance and the private Italian pharmaceutical group Alfa Wassermann have signed an exclusive development and commercialisation agreement worth up to $63.5 million plus royalties from sales for the US company's oral 5-HT4 agonist velusetrag (TD-5108) as a treatment for gastrointestinal motility disorders.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.